Status:
COMPLETED
A Comparison of the Drug Telbivudine (LdT) and Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis.
Lead Sponsor:
Mayo Clinic
Collaborating Sponsors:
Merck Sharp & Dohme LLC
Conditions:
Hepatitis B
Cirrhosis
Eligibility:
All Genders
18-70 years
Phase:
PHASE3
Brief Summary
This trial is being done to see if the investigational drug, LdT (Telbivudine), is safe and effective in the treatment of hepatitis B infection. In addition to this, we will be looking at the comparis...
Detailed Description
This study is a randomized, double-blinded trial looking at the drug Telbivudine (LdT) and comparing it to the drug lamivudine in patients with chronic hepatitis B and evidence of Cirrhosis. Interest...
Eligibility Criteria
Inclusion
- Patients with chronic hepatitis b with evidence of cirrhosis, who are at least 18 to 70 years old, may be eligible to participate in this study.
Exclusion
Key Trial Info
Start Date :
June 1 2004
Trial Type :
INTERVENTIONAL
End Date :
August 1 2007
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT00275652
Start Date
June 1 2004
End Date
August 1 2007
Last Update
March 23 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic
Rochester, Minnesota, United States, 55905